Path to Smart Manufacturing and Intelligent Development within Industry 4.0 – Building an Integrated Sensing Strategy

Path to Smart
Over the years there have been many frames of reference on the use of process analytical technology (PAT) in the commercial manufacturing space including monitoring, closed-loop control, quality control/real-time release, advanced process control, quality by design, Industry 4.0, etc.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Securing new drug development by establishing and maintaining phase-appropriate RSM designation from development to commercial launch

This webinar will discuss WuXi STA’s practice on overall RSM strategy, focusing on: Starting material evolution, RSM designation, Risk mitigation for potential regulatory push-back
Watch Now

A Comprehensive Review of Biomarker Endpoints in In Vivo Models of Parkinson’s Disease

Charles River

Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
Watch Now

Accelerating Precision Medicine by Pairing Next-Generation Sequencing (NGS) Kits with Ready-to-Use Analysis Workflows

In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.
Watch Now

Top 4 Quality Trends for 2019 Pharma Quality Outlook Survey

pharmtech

Economic performance could soon replace compliance as the leading quality goal for pharmaceutical companies. According to the 2019 Pharma Quality Outlook Survey, 66% of industry executives named compliance as a top goal, down 10% from last year. Meanwhile, more than one-third (39%) say that economic performance is now their top objective, a 4% increase.Join Sparta System's Steve McCarthy, VP of Digital Innovation, as he discusses key findings from this year's survey, which included responses from 161 professionals.
Watch Now

Spotlight

resources